Dashboard
Manage Tickers

XOMAXOMA Corp

Nasdaq xoma.com


$ 25.45 $ 1.75 (7.39 %)    

Friday, 10-May-2024 15:59:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 25.44
$ 24.93
$ 0.00 x 0
$ 0.00 x 0
$ 24.44 - $ 25.50
$ 13.48 - $ 27.00
10,959
na
291.82M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-08-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-10-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 03-10-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-06-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-07-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-04-2016 03-31-2016 10-Q
34 03-09-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-11-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

xoma-q1-2024-gaap-eps-086-misses-081-estimate
XOMA Q1 2024 GAAP EPS $(0.86) Misses $(0.8...
05/09/2024 12:38:26

XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.1...

hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
05/01/2024 11:03:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles
Xoma Has Acquired An Economic Interest In ...
04/30/2024 11:36:17

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...

cracking-the-code-understanding-analyst-reviews-for-xoma
Cracking The Code: Understanding Analyst R...
04/29/2024 14:00:22

leerink-partners-initiates-coverage-on-xoma-with-outperform-rating-announces-price-target-of-40
Leerink Partners Initiates Coverage On XOM...
04/29/2024 12:54:28

Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:XOMA) with a Outperform rating and announces Price ...

xoma-earns-9m-as-fda-grants-accelerated-approval-to-day-ones-ojemda-tovorafenib-for-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma
Xoma Earns $9M As FDA Grants Accelerated A...
04/25/2024 12:07:05

hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
04/25/2024 11:23:10

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles
XOMA Corp Entered Into A Merger Agreement ...
03/19/2024 20:15:36

As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered ...

hc-wainwright--co-maintains-buy-on-xoma-maintains-74-price-target
HC Wainwright & Co. Maintains Buy on XOMA,...
03/11/2024 16:10:48

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

recap-xoma-q4-earnings
Recap: XOMA Q4 Earnings
03/08/2024 12:40:05

xoma-fy-gaap-eps-404-may-not-be-comparable-to-205-estimate-sales-476m-miss-650m-estimate
XOMA FY GAAP EPS $(4.04) May Not Be Compar...
03/08/2024 12:35:50

XOMA (NASDAQ:XOMA) reported quarterly losses of $(4.04) per share which missed the analyst consensus estimate of $(2.05) by 97....

hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
02/16/2024 18:41:43

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

biotech-royalty-aggregator-xoma-to-acquire-small-cancer-drug-developer-kinnate-biopharma
Biotech Royalty Aggregator XOMA To Acquire...
02/16/2024 17:55:15

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in ...

Core News & Articles
XOMA Enters Agreement To Acquire Kinnate B...
02/16/2024 13:02:10

trading-halt-halted-at-75500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:55:00 a.m. ET - ...
02/16/2024 12:55:04

Core News & Articles
Talphera Announces $26M Capital Commitment...
01/18/2024 13:35:51

The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niya...

xoma-expands-its-commercial-royalty-and-milestone-portfolio-with-dsuvia-acquisition-provided-an-8m-non-dilutive-royalty-capital-solution-to-talphera
XOMA Expands Its Commercial Royalty And Mi...
01/18/2024 13:32:35

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial...

xoma-to-make-1m-milestone-payment-to-ladrx-reveals-fda-acceptance-of-zevras-arimoclomol-nda-filing-for-niemann-pick-disease-type-c
XOMA To Make $1M Milestone Payment To LadR...
01/11/2024 21:11:08

In June 2023, XOMA announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to ac...

xoma-names-owen-hughes-as-ceo-and-jack-wyszomierski-as-chairman-of-board
XOMA Names Owen Hughes As CEO And Jack Wys...
01/08/2024 12:44:38

Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023.

xoma-corporation-has-authorized-xomas-first-stock-repurchase-program-which-permits-the-company-to-purchase-up-to-50m-of-common-stock-through-january-2027
XOMA Corporation Has Authorized XOMA's Fir...
01/02/2024 12:33:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION